Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line. (3rd July 2016)

• Record Type: Journal Article
• Authors: Bakhtiari, Elham; Hosseini, Azar; Boroushaki, Mohammad Taher; Mousavi, Seyed Hadi
• Is Part Of: Journal of chemotherapy. Volume 28:Number 4(2016:Aug.)
• Page Start: 314
• Page End: 320
• Publication Date: 2016-07-03
• Subjects: Bay11-7082 -- Cytotoxicity -- MCF-7 -- Olmesartan; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947815Y.0000000055
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Objective: Over expression of renin–angiotensin system (RAS) and nuclear factor-kappaB (NF-kappaB) have major role in many cancers. In this study, role of angiotensin II (Ag II) and NF-kappaB pathway in breast cancer cell line (MCF-7) proliferation were studied using olmesartan (as a novel Ag II antagonist) and Bay11-7082 (as NF-kappaB inhibitor). Materials and Methods: Cells were treated with different concentrations of olmesartan and Bay11-7082.Cell proliferation was determined by 4, 5-Dimethylthiazol-2-yl, 2, 5-diphenyl tetrazolium (MTT) assay. Apoptotic cells were evaluated using PI staining of DNA fragmentation. Results: Olmesartan and Bay11-7082 decreased cell viability. Combination of olmesartan with Bay11-7082 also decreased cell viability as compared with single agent treatments. Results showed that apoptosis is involved in olmesartan and Bay11-7082-induced toxicity. Conclusion: Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future.